Table 3. Study findings evaluating IV... | American Society of Hematology

Table 3.

Study findings evaluating IV iron use for IDA in patients presenting to the ED: hematologic improvement outcome

Reference	Study design	N	Intervention*	Primary outcome: hematologic improvement
Reference	Study design	N	Intervention*		Pre	Post	P
Quintana-Díaz et al¹⁷	Pre–post study	202	IV iron in a “fast-track anemia clinic”	Hb, g/dL	8.3 ± 1.4	12.2 ± 1.8	.001
				Hematocrit, %	28 ± 2	39 ± 6	.001
				Ferritin, ng/mL	27 ± 55	320 ± 287	.001
Fabra et al¹⁶	Pre–post study	35	IV iron	Hb, g/dL	9	11.6	“Significant”
				Hematocrit, %	29.76	37.3	“Significant”
				Ferritin, ng/mL	47.2	197.6	“Significant”

Reference	Study design	N	Intervention*	Primary outcome: hematologic improvement
Reference	Study design	N	Intervention*		Pre	Post	P
Quintana-Díaz et al¹⁷	Pre–post study	202	IV iron in a “fast-track anemia clinic”	Hb, g/dL	8.3 ± 1.4	12.2 ± 1.8	.001
				Hematocrit, %	28 ± 2	39 ± 6	.001
				Ferritin, ng/mL	27 ± 55	320 ± 287	.001
Fabra et al¹⁶	Pre–post study	35	IV iron	Hb, g/dL	9	11.6	“Significant”
				Hematocrit, %	29.76	37.3	“Significant”
				Ferritin, ng/mL	47.2	197.6	“Significant”

Studies listed in this section did not include control or comparator group.